New Delhi, Sep 2 (UNI) Pharmaceutical firm Strides Arcolab today said it has received US Food and Drug Administration (USFDA) approval for its two new drugs used for normalising blood circulation.
The company has received Abbreviated New Drug Application (ANDA) approval for two drugs-- Dexamethasone Injection and Dexamethasone Sodium Phosphate-- from USFDA.
The drugs, used to treat fluid retention and swelling in the brain, normalise blood circulation due to surgical or accidental trauma and also in the treatment of inflammatory disorders like asthma and arthritis.
The products are licenced to Akorn-Strides, a joint venture between Nasdaq-listed Akorn Inc and Strides Arcolab.
The JV has now received 11 ANDA approvals out of the 18 filed till date.
UNI AK SG SSC1201